Deborah Layton - Concepedia

Author

Deborah Layton

Drug Safety Research Unit ORCID

Also Known As

D Layton, D Nielsen, D. LAYTON, D. Layton, Deborah Layton, K Gurung, D. Layton, S. Shakir, S. Shakir , S. Shaklr

108

Publications

1.8K

Citations

H-Index

Concepts

All Affiliations

Drug Safety Research Unit University of Portsmouth University of Southampton University Medical Center Utrecht IQVIA (United Kingdom)

About

Deborah Layton is an author at Drug Safety Research Unit specializing in medicine, pharmacotherapy, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	17	19	835
2	Public Health	4	4	231
3	Health Sciences	2	2	86
4	Social Sciences	2	2	90
5	Engineering	1	1	31

Deborah Layton

Publications

1.4K

Citations

H-Index

Page 1

	Year	Citations
Prescription-event monitoring and reporting of adverse drug reactions Emma Heeley, Jane Riley, Deborah Layton, The Lancet Drug SafetyDrug HypersensitivityDrug Information SystemPatient SafetyPharmacology	2001	127
Causal Association in Pharmacovigilance and Pharmacoepidemiology Saad Shakir, Deborah Layton Drug Safety Drug SafetyBehavioral PharmacologyCausal AssociationCausal InferencePharmacovigilance	2002	120
Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Deborah Layton, David W. Clark, Gillian Pearce, European Journal of Clinical Pharmacology PsychiatryMedicinePsychotropic MedicationSelective SerotoninPsychopharmacology	2001	70
Comparison of incidence rates of cerebrovascular accidents and transient ischaemic attacks in observational cohort studies of patients prescribed risperidone, quetiapine or olanzapine in general practice in England including patients with dementia Deborah Layton, Scott Harris, Lynda V. Wilton, Journal of Psychopharmacology Elderly PatientsCerebrovascular DiseasePharmacotherapyPrescription-event MonitoringAdverse Drug Reaction	2005	67
Comparison of the incidence rates of thromboembolic events reported for patients prescribed celecoxib and meloxicam in general practice in England using Prescription-Event Monitoring (PEM) data Deborah Layton British journal of rheumatology	2003	55
Serious Skin Reactions and Selective COX-2 Inhibitors Deborah Layton, Vanessa Marshall, A. Boshier, Drug Safety Medicinal ChemistryMedicineSelective Cox-2 InhibitorsClinical DermatologyPharmacotherapy	2006	49
Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring data Deborah Layton British journal of rheumatology	2003	48
Influenza H1N1 (swine flu) vaccination: a safety surveillance feasibility study using self‐reporting of serious adverse events and pregnancy outcomes Isla S. Mackenzie, Thomas M. MacDonald, Saad Shakir, British Journal of Clinical Pharmacology	2011	47
Safety Profile of Tolterodine as Used in General Practice in England Deborah Layton, Gillian Pearce, Saad Shakir Drug Safety Drug SafetyMedicinePatient SafetyPoisoningGeneral Practice	2001	45
Comparison of the Risk of Drowsiness and Sedation between Levocetirizine and Desloratadine Deborah Layton, Lynda Wilton, A. Boshier, Drug Safety SleepMedicineAnesthesia PracticeNeuropharmacologyPharmacotherapy	2006	45

Page 1